SemiBioSys and Tasly Pharmaceutical Joint Venture Receives Chinese Gov’t Approval and Business Licence

Calgary-based SemBioSys Genetics Inc. announced that its product and platform development collaboration agreement with Tasly Pharmaceutical Co., Ltd of Tianjin, China, and its wholly-owned subsidiary Tasly US has received all necessary Chinese government approvals and the business license for the newly formed company based in Tianjin, China, Tasly-SemBioSys Bio-Pharmaceutical, Technology Co., Ltd. The new joint venture company will commercialize healthy living, nutritional, and pharmaceutical products utilizing Tasly and SemBioSys’ plant-based technology and expertise. SemBioSyst Genetics is a health and wellness company that utilizes its patented plant seed-based oilbody and genetic expression technology platforms to develop high-value proteins, oils, and drug candidates in oil seed plants. Tasly is a high-tech company that focuses on modern TCMs, chemical & biological drugs, healthcare products, and functional foods.